Executive Committee

Anand Mahadev

Assistant Professor of Radiation Oncology Harvard Medical School, Radiation Oncologist, Beth Israel Deaconess Medical Center. Dr. Mahadevan completed his surgical and oncology training in UK. After his fellowship training in the Harvard Radiation Oncology program, he went on to become a staff radiation oncologist at the Beth Israel Deaconess Medical Center in Boston. He is currently the chief of Head and Neck, Neuro, Cutaneous and Stereotactic Radiation divisions. He has developed the field of SBRT in New England, with particular interest in brain tumors, liver tumors, pancreas cancers and Oligometastasis. He is also the assistant program director for the Harvard Radiation Oncology program. He is executive committee member and lecturer of ACMES.

Julian Wu

Associate Chairman of the Department of Neurosurgery, professor at Tufts University School of Medicine. Dr. Wu is a leading expert in brain tumor surgery, Gamma Knife radiosurgery, and the molecular genetics of primary and metastatic brain tumors.  He is also the Associate Chairman of the Department of Neurosurgery, Chief of the Division of Neurosurgical-Oncology, Co-Director of the Boston Gamma Knife Center (the only Gamma Knife center in Massachusetts and Northern New England), and Director of the Neurosurgical Residency Training Program at Tufts Medical Center. He is executive member and lecturer of ACMES.

Kan Liu

Assistant Professor in Cardiology, Upstate Heart and Vascular Center, SUNY Upstate Medical University. Dr. Kan Liu currently serves as an invasive and non-invasive cardiologist in Central New York State, and the Fellow of American College of Cardiology (FACC).  He became the Director of Echocardiography Lab, Cardiovascular Center at SUNY Upstate Medical University in 2010. He earned his PhD from the Departments of Internal Medicine and Cellular Biology at the University of Alabama at Birmingham  and his MD from Sun Yat-Sen University of Medical Sciences in Guangzhou, China.  Dr. Liu has been working on patient care and conducting basic/clinical research in cardiovascular disease in US for over 15 years. He serves as the principle investigator for multiple active research grants and nationwide clinical trails in US. He is one of authors of the prestigious clinical book “The Washington Manual@ Cardiology Consult”, and have numerous high profile publications. He is executive  member  and lecturer of ACMES.


Susan Liang

Dr.Liang  is an Assistant Professor of Ophthalmology, Tufts University School of Medicine. In addition to specializing in glaucoma lasers, surgery, and cataract surgery, Dr. Liang is dedicated to providing exceptional care to older patients with glaucoma, cataracts and other eye diseases. She is passionate about helping older patients, especially those with multiple medical problems, improve function and quality of life through coordinated eye care with the patient’s other health care providers.  She completed a Faculty Scholar’s Fellowship in Geriatrics at the Boston Medical Center. The American Geriatrics Society has awarded her a grant to develop educational content for ophthalmology residents. She was awarded Best Clinical Instructor in 2008 for her work in training ophthalmology residents at Boston University School of Medicine. Dr. Liang has lectured locally and nationally on glaucoma topics. She is executive member  and Lecturer of ACMES.

Jingtai Cao

Dr. Cao is Associate Director of Ophthalmology and Inflammatory Diseases in Regeneron Pharmaceuticals, Inc. USA. He received his medical degree from Hebei Medical University and his Ph.D. degree in from Beijing University in China. Dr. Cao completed his Post-doctoral fellowship at the Wilmer Eye Institute of the Johns Hopkins University, and subsequently appointed as Instructor, then Adjunct Assistant Professor in Department of Ophthalmology He has a wide range of clinical and basic research experiences in ocular diseases and  holds 18 patents and applications. Dr. Cao is the recipient of a number of awards in Ophthalmology Society. He has also published over 80 peer-reviewed scientific papers, book chapters, and abstracts on eye diseases. Since 2000, Dr. Cao has been engaged in instituting the ophthalmology research team at Regeneron With his innovations and leadership in preclinical research, one of his great contribution and achievements is the VEGF Trap-Eye, (EYLEA®, Aflibercept injection) a new anti-VEGF drug which was approved on November 18, 2011 by FDA for treatment of neovascular Age-related Macular Degeneration (AMD). He is executive committee member and Lecturer of ACMES.

Ming Wong

Dr.Wong has been practice in Boston area for more than 30 years as a family physician and alternative medicine provider, he graduated from Sun yet sin medical school in 1970, and Passed ECFMG in 1980 (Earliest one from mainland China), he got his residency training in Umass medical center (family practice) .  He is also a community leader and served two year as president of Camp, organized Community health education exhibitions several times in Chinatown. He wrote two Books: “Traditional Chinese Medicine and Metaphysics” and “The theory of Major Confucian and Western philosophy.” He is executive committee member of ACMES, editor and author of North American Journal of Medicine and health.

Shen Luan

Dr.Luan is the Co-Founder and Chief Operating Officer, Berg Diagnostics. Intrigued by systematically exploring and understanding the molecular profile underlying the pathophysiology of human disease. Excited about utilizing the state-of-the-art mass spectrometric technologies to develop molecular diagnostic solutions which facilitate clinical decision making, improve quality of patient care, and minimize costs of disease management. Shen Luan is currently Chief Operating Officer at Berg Diagnostics .Shen joined Cytotech Labs in 2009 as Director of Bioanalytical and Diagnostics. He was named as Vice President of Bioanalytical and Diagnostics in 2010. He was appointed as President and Chief Technology Officer in 2010 for the newly formed Berg Diagnostics. He leads the development and implementation of Berg Diagnostics’ technology platforms, directs business development efforts, as well as provides corporate strategy. He was a Technical Product Manager of Waters Corporation responsible for LC/MS and LC/MS/MS system solutions and laboratory informatics. Prior to joining Waters Corporation in 2004, he was with Thermo Fisher Scientific for 9 years and has held various management positions including Engineering Manager, Research Manager, and Product Manager. He has solid business experience across the product lifecycle including design, development, project management, commercialization, manufacturing, supply chain, quality assurance, and regulatory compliance. He received a Ph.D. in Analytical Chemistry from Iowa State University and a B.S. in Analytical Chemistry from Peking University. He authored and co-authored 10 peer-reviewed publications and 29 scientific meeting presentations. He holds a Lean - Six Sigma Black Belt certificate. He is executive member of ACMES.

Jiguang Zhu

Dr. Zhu is an associate professor and neuro-oncologist at Neurosurgery and Neurology Departments of UT Houston/Mischer Neuroscience Institute of Memorial Hermann. He obtained his B.S. in Biology in Shandong University, Jinan, China in 1984. He came to USA in 1985 as a CUSBEA scholar (China-US Biochemistry Exchange Application). After obtaining Ph.D. in Molecular Biology at State University of New York, Buffalo, New York, he did post-doctoral training in Children Hospital and Brigham & Woman’s Hospital, Harvard Medical School in Boston, MA. In 1999, he obtained MDCM in McGill University, Montreal, Canada.  Dr. Zhu finished Neurology residency in Tufts University School of Medicine and fellowship in Neuro-Oncology in Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts. Before moving to UT Houston/Memorial Hermann in September, 2010, Dr. Zhu was an assistant professor and attending in Neurology for 5 years in Tufts Medical Center, Boston, MA. Dr. Zhu is specialized in neuro-oncology seeing patients with primary and metastatic brain and spine tumors. He interested in achieving more efficacious therapies for malignant gliomas through clinical trials and understanding of mechanism of tumorigenesis and drug resistant of tumor cells working in collaboration with research scientists. He is executive committee member  of ACMES and To Cure Autism Institute, specialty editor of North American Journal of Medicine and Science.